Peptides for Night Sweats & Hot Flashes — Evidence-Based Overview

How peptide Targets Peptides for Night Sweats & Hot Flashes

Night sweats and hot flashes — collectively termed vasomotor symptoms (VMS) — are among the most disruptive symptoms experienced during menopause, andropause, and various medical conditions. They result from dysfunction in the thermoregulatory center located in the hypothalamic preoptic area, where a narrowing of the thermoneutral zone causes the body to initiate heat-dissipating responses (vasodilation, sweating) in response to tiny core temperature fluctuations that would normally be tolerated. In menopausal women, declining estrogen levels destabilize hypothalamic KNDy (kisspeptin/neurokinin B/dynorphin) neurons, which directly regulate thermoregulation. Night sweats specifically disrupt sleep architecture, compounding the problem with daytime fatigue, cognitive impairment, and mood disturbances. While hormone replacement therapy remains the most effective treatment for menopausal vasomotor symptoms, peptide-based approaches offer alternative or complementary strategies for individuals who cannot or prefer not to use hormonal therapy.

Kisspeptin-10 is the most mechanistically relevant peptide for vasomotor symptoms because it directly engages the hypothalamic neurocircuitry responsible for thermoregulatory dysfunction. Kisspeptin neurons in the hypothalamic arcuate nucleus are central components of the KNDy neuronal network that regulates both reproductive hormone release and body temperature. In menopause, the loss of estrogen's inhibitory feedback on KNDy neurons leads to their hyperactivation, which drives both the characteristic hormonal changes and the vasomotor instability. Kisspeptin-10 activates GPR54 (KISS1R) receptors and modulates the pulsatile release of gonadotropin-releasing hormone (GnRH), which influences the entire hypothalamic-pituitary-gonadal axis. Research into kisspeptin signaling has been fundamental to understanding why menopause causes hot flashes, and neurokinin B receptor antagonists (which target another component of the same KNDy network) have been approved for menopausal VMS. Kisspeptin-10 itself remains investigational for this indication, but the underlying neuroscience is well-established and has already yielded approved therapeutics targeting the same pathway.

DSIP (delta-sleep-inducing peptide) addresses the sleep disruption component of night sweats, which is often as debilitating as the sweating itself. DSIP modulates delta-wave sleep architecture — the deep, restorative phase of sleep during which thermoregulation, tissue repair, and hormonal regulation occur most actively. By promoting more consolidated slow-wave sleep, DSIP may reduce the frequency of nocturnal arousals triggered by vasomotor episodes and improve overall sleep quality. DSIP also influences hypothalamic-pituitary function and has been shown to modulate cortisol and growth hormone secretion patterns, both of which follow circadian rhythms that are disrupted in individuals experiencing chronic night sweats. The evidence for DSIP comes primarily from preclinical studies and limited early human research, and it should not be considered a proven treatment.

Selank, a synthetic heptapeptide with anxiolytic and neuromodulatory properties, is relevant because stress and anxiety significantly amplify vasomotor symptoms. The hypothalamic thermoregulatory center receives input from stress-related brain regions, and elevated sympathetic nervous system activity lowers the threshold for hot flashes. Selank modulates GABAergic and serotonergic neurotransmission — both systems directly involved in thermoregulation — and reduces anxiety without the sedation or dependence associated with benzodiazepines. Serotonin reuptake inhibitors (SSRIs and SNRIs) are used off-label for hot flashes, validating the relevance of serotonergic modulation in vasomotor symptom management. Oxytocin, primarily recognized for its roles in social bonding and reproduction, has hypothalamic effects that influence thermoregulation, stress responses, and sleep quality. Oxytocin receptors are present in the hypothalamic preoptic area where thermoregulatory decisions are made, and oxytocin signaling may contribute to stabilizing the thermoneutral zone. Intranasal oxytocin has been studied for its effects on sleep quality and stress reactivity, though not specifically for vasomotor symptoms.

Managing night sweats and hot flashes effectively requires identifying the underlying cause. Menopausal vasomotor symptoms have well-characterized pathophysiology, but night sweats can also result from medications (antidepressants, opioids, hormone-modifying drugs), infections, lymphoma, endocrine disorders (thyroid dysfunction, carcinoid syndrome), and obstructive sleep apnea. A thorough medical evaluation is essential before attributing night sweats to hormonal changes alone. For menopausal VMS, hormone replacement therapy remains the most effective evidence-based treatment, and the risk-benefit profile has been substantially clarified since earlier controversies. Peptide approaches should be considered within this broader clinical context, not as first-line replacements for proven therapies.